SQZ, Roche expand deal to jointly develop cancer cell therapies

By Mark Zipkin | Oct 15, 2018 | 2:41 PM GMT

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy strategies.

The

Read the full 378 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE